SIC
BBIO icon

SJS Investment Consulting’s BridgeBio Pharma BBIO Stock Holding History

SJS Investment Consulting’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.76K Buy
37
+17
+85% +$1.19K ﹤0.01% 1641
2026
Q1 		$1.49K Sell
20
-135
-87% -$9.79K ﹤0.01% 1344
2025
Q4 		$11.9K Buy
155
+139
+869% +$9.12K ﹤0.01% 745
2025
Q3 		$832 Buy
16
+3
+23% +$146 ﹤0.01% 1076
2025
Q2 		$562 Sell
13
-9
-41% -$327 ﹤0.01% 1075
2025
Q1 		$761 Buy
22
+15
+214% +$506 ﹤0.01% 1096
2024
Q4 		$193 Sell
7
-18
-72% -$465 ﹤0.01% 1463
2024
Q3 		$637 Buy
25
+2
+9% +$53 ﹤0.01% 1242
2024
Q2 		$583 Buy
23
+4
+21% +$109 ﹤0.01% 1236
2024
Q1 		$588 Buy
19
+2
+12% +$68 ﹤0.01% 1232
2023
Q4 		$687 Buy
17
+3
+21% +$90 ﹤0.01% 1115
2023
Q3 		$370 Buy
14
+5
+56% +$142 ﹤0.01% 1314
2023
Q2 		$155 Buy
9
+4
+80% +$60 ﹤0.01% 1453
2023
Q1 		$83 Buy
5
+3
+150% +$35 ﹤0.01% 1478
2022
Q4 		$15 Hold
2
– – ﹤0.01% 1583
2022
Q3 		$0 Buy
+2
New +$21 ﹤0.01% 1056
2022
Q1 		$0 Buy
+1
New +$10 ﹤0.01% 734

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

SJS Investment Consulting's BBIO Position: Q2 2026 in Review

SJS Investment Consulting increased its BridgeBio Pharma (BBIO) stake by 85% in Q2 2026, buying an estimated $1.19K and bringing the position to 37 shares worth $2.76K. The position accounts for ﹤0.01% of the portfolio, ranked #1641.

SJS Investment Consulting first reported a position in BBIO in Q1 2022 and has held it in 17 quarters since. The position peaked at $11.9K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • SJS Investment Consulting held 37 shares of BridgeBio Pharma worth $2.76K as of Q2 2026.
  • SJS Investment Consulting bought 17 BridgeBio Pharma shares in Q2 2026, an estimated $1.19K.
  • BridgeBio Pharma made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1641 holding.
  • SJS Investment Consulting first reported a position in BridgeBio Pharma in Q1 2022 and has held it in 17 quarters since.
  • SJS Investment Consulting's BridgeBio Pharma position peaked at $11.9K in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.